Making the Most of the EU's Regulatory Resources
This article was originally published in SRA
Executive Summary
The European Generic medicines Association's 8th regulatory and scientific affairs conference took place on 29-30 January in Amsterdam. The event covered a number of issues affecting the generic medicines sector, such as making the most efficient use of existing resources by national competent authorities in order to achieve an efficient regulatory system in Europe, improvements to the variations regulations that will affect both authorities and industry, and the implementation of electronic submissions. It also discussed current experience and advice on how to update the patient information leaflet and the summary of product characteristics of generic medicines to reflect changes to the reference product, and touched on the European Commission's inquiry into competition in the EU pharmaceutical sector.
You may also be interested in...
Vivalink Partners With Rett Syndrome Research Trust To Accelerate Research In Rare Disease
Vivalink will provide ECG wearable technology to monitor patients in RSRT’s Vibrant study, which is aimed at assessing autonomic dysfunction in children with Rett syndrome.
Cidara Offloads Rezzayo, Will Focus On Universal Flu Preventative
Cidara conferred global rights to its novel antifungal to marketing partner, Mundipharma, while reacquiring a flu prophylaxis it licensed to J&J in 2021 and gaining $240m in new funding to back development.
Pharma Can Pursue Claims Against Providers For 340B Duplicate Discounts In Medicaid Managed Care, HRSA Says
The statement, which is part of a final rule on the 340B administrative dispute resolution process, could facilitate manufacturer efforts to seek repayments from hospitals in such cases.